In a viral roadshow clip, Anthropic CEO Amoday predicted that cancer, Alzheimer's disease, heart disease and mental illness will be a thing of the past on a time scale of less than ten years. He also emphasized that AI companies must properly handle risks, win social trust, and establish viable business models. (Preliminary summary: Anthropic acquires a pharmaceutical company to personally develop new drugs for rare diseases, with human trials as soon as 2028) (Background supplement: Anthropic announced that it will "personally develop new drugs," but experts poured cold water: FDA certification will take at least 10 years) Anthropic has released the video on its official roadshow page. In a roadshow clip circulated in the early morning of November 11th, Taipei time, CEO Dario Amodei predicted that cancer, Alzheimer's disease, heart disease and mental illness will become a thing of the past on a time scale of less than ten years. The conversation juxtaposes the medical potential of artificial intelligence (AI) with corporate responsibility. On the one hand, Amoday paints a picture of the prospect of humanity being free from major diseases, and on the other hand, he emphasizes that while AI companies can bring benefits, they must carefully handle technical risks. Amodei predicted that in less than ten years, four major diseases will become a thing of the past. Amodei first listed cancer, Alzheimer's disease, heart disease and mental illness, and then made a judgment in less than ten years. He describes this future with his own views, pointing the value of AI to health problems that have long plagued mankind. He went on to say that if we can do things right, mankind will have the opportunity to create an "age of miracles" and solve problems that have been difficult to break through for thousands of years. This optimistic vision is connected to his requirements for the way AI is developed and deployed. Only by handling risks well can we win social trust and operating space. Amoday believes that companies that can handle risks well will have a better chance of gaining social trust and gain legitimacy for continued operations and development. Whether society believes that companies can properly realize the benefits of AI is an important condition for the company's long-term development. Discussing how to realize these benefits, he again emphasized that companies must carefully address the various ways in which technology can go wrong while maintaining viable commercial operations. In his narrative, technical benefits, risk management and business models must be advanced together. A long article in 2024 has charted the path to accelerating medical research. In his long article "Machines of Loving Grace" in October 2024, Amoday proposed the idea of ​​​​compressing 50 to 100 years of biomedical progress into 5 to 10 years. The derivation framework of that article starts from the emergence of powerful AI as defined by it. In the article, different diseases also have different breakthrough directions: the cancer part talks about eliminating most cancers, but rare types that are difficult to treat may still be left; Alzheimer's disease focuses on prevention, and the damage that has been done may be difficult to reverse. Heart disease is included in the effort to improve the treatment of other diseases, while mental illness is expected to be cured or prevented through multiple lines of research. This concept values ​​the ability of AI to participate in designing experiments and improving research methods, so that acceleration does not only occur in data analysis, but extends to the entire scientific research process. Returning to the clip that circulated this time, Amodei connected the medical vision with the long-term role of AI companies: the technology must bring substantial benefits, and the company must have the ability to control risks and maintain commercial operations in order to continue to obtain social support and promote these researches. Related reports: Claude’s self-designed protein has a hit rate of 35%, and Anthropic is accelerating the development of new drugs? AI finds potential new tool for gene editing: Claude dug out CRISPR-like enzymes from 1.9 billion data. DeepMind uses AI to predict 9 billion DNA mutations to help find the cause of rare diseases (free and open to academia) AI can now diagnose the "silent killer" pancreatic cancer in advance〈Anthropic CEO predicts: In less than ten years, diseases such as cancer and Alzheimer's disease will become a thing of the past. This article was first published in BlockTempo's "Dongqu Dongzhi - the most influential blockchain news media".